At the conclusion of their cycle, hematocrit ranges had enhanced by three%-stage compared with baseline. The rise was not affiliated with extended use or greater AAS dose. A cause for this might be that, beyond a certain volume of androgenic activity, no further more enhance of hematocrit happens: a ‘ceiling outcome’. Notably, While only 5% of